Zobrazeno 1 - 10
of 15
pro vyhledávání: '"nedrobnocelični rak"'
Publikováno v:
Onkologija, Vol 22, Iss 1, Pp 60-66 (2018)
Dopolnilna kemoterapija (KT) na bazi platine je srednje močan dejavnik tveganja za pojav febrilne nevtropenije (10- do 20-odstotna incidenca) pri operabilnem raku pljuč. Namen raziskave je bil preveriti pojavnost febrilne nevtropenije (FN) in nevtr
Externí odkaz:
https://doaj.org/article/9e3c3aed33054a1f90ce85a84e6e85ef
Autor:
Podgoršek, Eva
UVOD IN NAMEN: Rak pljuč in kronična obstruktivna pljučna bolezen (KOPB) imata podobne simptome ter dejavnike tveganja. Zaradi tega sta lahko bolezni prisotni sočasno ali pa se pri eni sprva pomisli na drugo. Namen raziskave je bil opisati, kako
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3505::41aff027105bd146145fe08f305e6cde
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=146739
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=146739
Autor:
Rus, Zala
Pembrolizumab je monoklonsko protitelo, ki z vezavo na imunske kontrolne točke ponovno aktivira zavrt imunski sistem in pomaga telesu prepoznati, napasti in uničiti rakave celice. V začetnih kliničnih študijah je bil pembrolizumab odmerjan glede
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3505::881baa93699a7e54e8e3b305d6e95d86
https://hdl.handle.net/20.500.12556/RUL-143404
https://hdl.handle.net/20.500.12556/RUL-143404
Autor:
Gartner, Nika
Nedrobnocelični rak pljuč (NDRP) je najpogostejša oblika raka pljuč. Pogosto je odkrit v razsejani obliki in zanj je značilna visoka umrljivost, s 5-letnim preživetjem pod 10 %. Na področju sistemskega zdravljenja razsejanega NDRP se je po let
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3505::5002d38f94c58ad9ca34f3c0ebc24c0e
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=136800
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=136800
Publikováno v:
Onkologija, Vol 15, Iss 2, Pp 83-87 (2011)
Petletno preživetje bolnikov s pljučnim rakom je slabo, samo 12-odstotno, in se v zadnjih 15 letih ni bistveno izboljšalo. Standardno zdravljenje razsejanega nedrobnoceličnega raka pljuč (NDRP), ki je danes najpogostejši tip raka pljuč, je kem
Externí odkaz:
https://doaj.org/article/a6e48c1899bd4e34821d5830ac93cc50
Publikováno v:
Radiology and Oncology
Radiology and Oncology, Vol 53, Iss 3, Pp 357-361 (2019)
Radiology and oncology, vol. 53, no. 3, pp. 357-361, 2019.
Radiology and Oncology, Vol 53, Iss 3, Pp 357-361 (2019)
Radiology and oncology, vol. 53, no. 3, pp. 357-361, 2019.
Background The outcomes of patients with both lung cancer and idiopathic pulmonary fibrosis (IPF) are unfavorable. Therapeutic interventions for lung cancer such as surgery can cause acute exacerbation of IPF (aeIPF). This study aimed to assess the f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e8d57d58a7f2bc526d84bbce077a37c
http://europepmc.org/articles/PMC6765158
http://europepmc.org/articles/PMC6765158
Publikováno v:
Neoplasma, vol. 65, no. 1, pp. 140-146, 2018.
The standard treatment for inoperable locally advanced non-small cell lung cancer (LA NSCLC) includes concurrent or sequential chemotherapy (ChT) and radiation therapy (RT). Long term survival rates with these approaches remains only in the order of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a186fc35ba1cf47a3bfbe3d80e36365
https://hdl.handle.net/20.500.12556/DiRROS-12920
https://hdl.handle.net/20.500.12556/DiRROS-12920
Autor:
Valentinuzzi, Damijan
Immunotherapy with immune-checkpoint inhibitors has changed the paradigm of cancer treatment. For the first time in the history of oncology, it is possible to realistically expect complete remissions of metastatic disease in certain types of cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3505::2dd1a34ac6317f7a4e4bde8fd5fef706
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=120530
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=120530
Autor:
Luka Brcic, Izidor Kern
Publikováno v:
Translational lung cancer research, vol. 9, pp. 1-5, 2020.
Transl Lung Cancer Res
Transl Lung Cancer Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::116e27843bf30519abd8d4cd5259448b
https://dirros.openscience.si/Dokument.php?id=14612&dn=
https://dirros.openscience.si/Dokument.php?id=14612&dn=
Autor:
Gabriela Galffy, Milada Zemanova, Jacek Jassem, Tudor Ciuleanu, Christoph C. Zielinski, Marko Jakopović, Christiane Thallinger, Zhasmina Mihaylova, Dragana Jovanovic, Tanja Cufer, Peter Berzinec, Gyula Ostoros
Publikováno v:
The oncologist, vol. 25, no. 3, pp. e598-e601, 2020.
The Oncologist
The Oncologist
Background Treatment of non‐small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune‐oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a29411b1978e8cefbc7a8e5da52fb42
https://dirros.openscience.si/IzpisGradiva.php?id=12196
https://dirros.openscience.si/IzpisGradiva.php?id=12196